Drug intelligence / Profile preview

NW-531

Development stage: Preclinical
Lead developer: NeuraWell Therapeutics
Modality: Small Molecules

Overview

**NW-531** is an investigational small-molecule CNS program from NeuraWell Therapeutics for **major depressive disorder** and **treatment-resistant depression**. NeuraWell describes NW-531 as a unique molecule used in combination with an undisclosed broad-action existing antidepressant and a reformulated delivery approach intended to mitigate potentially serious side effects and support treatment adherence. The molecular identity, co-administered antidepressant, biological targets, route, dosage form, release characteristics, and clinical phase have not been publicly disclosed.

Beyond the preview

Go deeper on NW-531.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NW-531.

Explore the full profile